

THE PRACTICE AND PROMISE OF NGS TISSUE TESTING FOR TUMOUR-AGNOSTIC PRECISION THERAPEUTICS

Chair

Vivek Subbiah, Houston, TX, USA

Co-Chair

Javier Hernandez Losa, Barcelona, Spain

SATURDAY, 10 SEPTEMBER 2022

13:00-14:30 CEST, CONGRESS HALL 7 - AUDITORIUM 7.3.H - HONFLEUR

| | | |
|-------|--|--|
| 13:00 | Welcome and introduction | Javier Hernandez Losa, Barcelona, Spain |
| 13:05 | Tumour-agnostic precision therapeutics in molecular oncology-target versus tissue context: Evidence for benefit and taxonomy considerations | Vivek Subbiah, Houston, TX, USA |
| 13:20 | Next-generation sequencing (NGS) tissue testing in the search of actionable biomarkers in solid tumours: When is it indicated? | Benedikt Westphalen, Munich, Germany |
| 13:35 | Optimally integrating tumour tissue NGS in the care pathway: Preanalytics, analytics, cost and reimbursement | Javier Hernandez Losa, Barcelona, Spain |
| 13:50 | The non-small cell lung cancer paradigm in translating NGS information to clear actionable insights: Standardised reporting, molecular tumour boards and decision-support systems | Oliver Gautschi, Lucerne, Switzerland |
| 14:05 | Q&A and discussion | All speakers |
| 14:25 | Concluding remarks | Vivek Subbiah, Houston, TX, USA |

This educational activity is provided by ESMO and supported by Lilly and Thermo Fisher Scientific.

